Juriaan Wossink / shutterstock.com
Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck, CRISPR-Cas9, patents, portfolio, US, University of California, Broad Institute, USPTO, IP, gene-editing